Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Prostate Cancer Clinical Trials in Dallas | 283 Studies

Clinical Trials Prostate CancerDallas

Prostate Cancer Clinical Trials in Dallas

Find 283 clinical trials for prostate cancer near Dallas, Texas. Connect with research centers in your area.

All Prostate Cancer trials nationwide All trials in Dallas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 161-180 of 283 trials

TerminatedDocetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer PatientsThe primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus…NCT00133224·Anchorage, Alaska and 114 others

Prostate Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedA Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus…NCT00571675·Colorado Springs, Colorado and 34 others

TerminatedStudy of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety, tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered…NCT04726332·Atlanta, Georgia and 4 others

CompletedEfficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerThe purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.NCT02200614·Homewood, Alabama and 403 others

CompletedStudy Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate CancerThis is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic…NCT00137436·Harvey, Illinois and 23 others

RecruitingStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy…NCT05519449·Birmingham, Alabama and 35 others

Active not recruitingSpaceIT Hydrogel System for Perirectal SpacingTo evaluate the safety and effectiveness of the SpaceIT™ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.NCT06451614·Laguna Hills, California and 25 others

CompletedA Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate CancerThe purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as…NCT02737332·Laguna Hills, California and 16 others

CompletedProvenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyProvenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate…NCT00065442·Laguna Hills, California and 70 others

Active not recruitingPhase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed…NCT06691984·Birmingham, Alabama and 163 others

Active not recruitingTesting the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate CancerThis phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene…NCT05828082·Phoenix, Arizona and 25 others

CompletedStudy of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneOpen-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard…NCT03602079·Sarasota, Florida and 9 others

Active not recruitingAntiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryThis randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy…NCT03070886·Mobile, Alabama and 312 others

RecruitingStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerThis phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants…NCT03678025·Gilbert, Arizona and 337 others

Active not recruitingA Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPCThe purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall…NCT02489318·Homewood, Alabama and 219 others

CompletedA Study of PRT2527 in Participants With Advanced Solid TumorsThis is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors.NCT05159518·Denver, Colorado and 7 others

Active not recruitingTTX-080 HLA-G Antagonist in Subjects With Advanced CancersTTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy…NCT04485013·Tucson, Arizona and 40 others

CompletedEvaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior ChemotherapyThis is a multi-centre, phase II, open-label, two-stage design, single-arm study in patients with hormone-refractory prostate cancer (HRPC) with advanced (rising PSA) and/or…NCT00278993·Denver, Colorado and 17 others

Completed"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskThis 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are…NCT00056407·Birmingham, Alabama and 931 others

Active not recruitingTesting the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE StudyThis phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer.NCT04484818·Duarte, California and 114 others

PreviousPage 9 of 15Next

Other Conditions in Dallas

Breast Cancer Lung Cancer Colorectal Cancer Melanoma Leukemia Lymphoma